Browsing by Author "Gelabert-Baldrich, Mariona"

Sort by: Order: Results:

  • An integrative study of protein-RNA condensates identifies scaffolding RNAs and reveals players in fragile X-associated tremor/ataxia syndrome
    Cid Samper, Fernando, 1991-; Gelabert-Baldrich, Mariona; Lang, Benjamin; Lorenzo Gotor, Maria de las Nieves; Ponti, Riccardo delli; Severijnen, Lies-Anne W.F.M.; Bolognesi, Benedetta; Gelpi, Ellen; Hukema, Renate K.; Botta Orfila, Teresa; Tartaglia, Gian Gaetano (Elsevier, 2018)
    Recent evidence indicates that specific RNAs promote the formation of ribonucleoprotein condensates by acting as scaffolds for RNA-binding proteins (RBPs). We systematically investigated RNA-RBP interaction networks to ...
  • HER-family ligands promote acquired resistance to trastuzumab in gastric cancer
    Sampera Borràs, Aïda, 1990-; Sánchez-Martín, Francisco Javier; Arpí Llucià, Oriol; Visa Turmo, Laura; Iglesias Coma, Mar; Menéndez, Silvia; Gaye, Élisabeth; Dalmases Massegú, Alba, 1982-; Clavé Safont, Sergi; Gelabert-Baldrich, Mariona; Tuxen Poulsen, Thomas; Kragh, Michael; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Rovira Guerín, Ana; Rovira Guerín, Ana; Montagut Viladot, Clara (American Association for Cancer Research (AACR), 2019)
    Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer ...
  • The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
    Sanchez Martin, Francisco Javier; Bellosillo Paricio, Beatriz; Gelabert-Baldrich, Mariona; Dalmases Massegú, Alba, 1982-; Cañadas Castillo, Israel, 1984-; Vidal Barrull, Joana; Martinez, Alejandro; Argiles, Guillem; Visa Turmo, Laura; Arpí Llucià, Oriol; Iglesias García, Mar; Rovira Guerín, Ana; Albanell Mestres, Joan; Tabernero Cartula, Josep; Montagut Viladot, Clara (American Association for Cancer Research, 2016)
    PURPOSE: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking